

August 18, 2020

The BSE Limited

Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai - 400 001
Scrip Code: 541540

The National Stock Exchange of India

Limited Exchange Plaza, Bandra-Kurla
Complex Sandra (E), Mumbai - 400 051
Scrip Code: SOLARA

Dear Sir/ Madam,

Sub: Change in Management / Appointment of Chief Financial Officer

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that Mr. Subhash Anand joins the company as the new CFO and will succeed incumbent Executive Director and CFO Mr. Hariharan Subramaniam who retires in March 2021

Mr. Subhash Anand will transition over the coming months with Mr. Hariharan Subramaniam and eventually succeed as Executive Director and CFO by the end of FY 2020 – '21.

Press release on appointment of Mr. Subhash Anand (with brief profile) is enclosed.

We request you to take the same on record.

Thanking you,

Yours Truly,

For Solara Active Pharma Sciences Limited



S. Murali Krishna
Company Secretary



Solara announces onboarding of new CFO

Subhash Anand joins Solara as the new CFO and will succeed incumbent Hariharan Subramaniam who retires in March 2021

Bangalore, August 19, 2020: Solara Active Pharma Sciences Limited (Solara), one of India's leading pure-play active pharmaceutical ingredients Company today announces the appointment of **Subhash Anand (Subhash) as the new Chief Financial Officer (CFO)** to succeed **Hariharan Subramaniam(Hari)** the incumbent CFO and Executive Director of the Company.

Subhash joins the Company from **PI Industries Limited(PIIL)** where he was the President and CFO. He brings a wealth of experience across the full array of the finance function. Before PIIL, he worked in Whirlpool, Sterlite Industries, Hindustan Copper Ltd and Calcom in senior finance roles. Subhash is a qualified AICWA (India) & Certified Management Accountant (CMA) from the Institute of Management Accountants (USA). With his rich experience and excellent track record, Subhash will strengthen the leadership team of Solara, as it enters the next phase of accelerating growth and delivering superior returns to all its stakeholders.

Subhash will transition over the coming months with Hari and eventually succeed Hari as Executive Director and CFO by the end of FY21. The Board appointed Hari in April 2017, and since then, Hari has been an integral part of the journey of Solara from being a new entrant in the API space to becoming a leading standalone API Company with scale, and scope.

About Solara Active Pharma Sciences

Solara Active Pharma Sciences Ltd (BSE-541540, NSE-SOLARA) headquartered in Bengaluru, India offers a basket of diversified, high-value Commercial APIs and Contract manufacturing services in over 75 countries. It has a manufacturing base comprising five globally compliant API facilities, with approvals including the USFDA, EU GMP and PMDA in Japan.

Investor / Analyst contact

Abhishek Singhal

Investor Relations Consultant

✉ abhishek.singhal@solara.co.in

Statutory and corporate affairs

Murali Krishna S

Raghavan. V

✉ investors@solara.co.in

☎ +91 44 4344 6700